Related Experiment Videos
Liver dysfunction associated with gold therapy for rheumatoid arthritis
The Journal of Rheumatology
|June 1, 1983
Summary
Gold therapy for rheumatoid arthritis can rarely cause jaundice, a liver condition. This study describes three cases of jaundice during chrysotherapy, highlighting its varied timing and severity.
Area of Science:
- Hepatology
- Rheumatology
- Pharmacology
Background:
- Gold therapy (chrysotherapy) is a treatment for rheumatoid arthritis.
- Hepatic toxicity is an uncommon side effect of gold therapy.
Observation:
- Three rheumatoid arthritis patients developed jaundice during chrysotherapy.
- Jaundice onset varied, occurring both early and late in treatment.
- Liver biopsies indicated intrahepatic cholestasis.
Findings:
- Jaundice during gold therapy can present with varying severity.
- Intrahepatic cholestasis is the observed liver pathology.
Implications:
- Clinicians should monitor for jaundice in patients undergoing gold therapy.
- Understanding this rare adverse effect is crucial for patient management and safety.